Paragon Bioservices, the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, announces today the promotion of key personnel and the addition of two industry veterans to its leadership team. Specifically, the Company appoints Philip Wills, PhD, as Chief Commercial Officer, John Conner as Chief Manufacturing Officer, and William "Bill" Thomas, Jr., PhD, as Chief Scientific Officer, and hires Randy Henrickson as VP of Manufacturing and Dermot McCaul as VP of Information Technology.